To: Joe Krupa who wrote (6493 ) 1/18/2001 9:18:47 PM From: Montana Wildhack Read Replies (2) | Respond to of 14101 Hi Joe, Nomura I believe it is the largest Japanese company of its type. Like many Japanese financial companies, it hasn't been doing that well lately but is certainly of a premier size. I don't know anyone who trades through them based in North America. On another topic, I would just make the comment that investing in Provalis does not reduce exposure to the success of Pennsaid in your portfolio - but does expose investors to another set of management who have not exactly had stellar performance. They appear to be improving their condition, but even solid success in Pennsaid, does not necessarily translate into successful shareprice unless the other products and their expected success are also understood and liked. Doesn't mean its not good. On Dimethaid, those bollinger bands are getting awfully tight and I suspect a breakout which at the moment appears to have more probability on the downside. On the other hand, the bids have recently appeared quickly in the 6.90 range and there has been no apparent desire to sell in this quiet period. Having seen the approval and UK deal in good time, and knowing the cash crunch is gone, I'm content to ride through to the next stage. I warned earlier and still expect late January and February to be a non-eventful period. I'm willing to be suprised; but, I would watch any margin a little more closely these next 6 weeks or so. Good luck to everyone. Don't forget DMX will have both an upfront payment and revenue this quarter. Can't launch in March without product. Last time we had income of any kind was mid 1999. And we've never had a profitable quarter. Wolf